B. Riley Lifts Earnings Estimates for Kymera Therapeutics

Key Points

• Investment analysts at B. Riley have raised their Q3 2025 earnings estimates for Kymera Therapeutics, now forecasting earnings per share of ($0.98) compared to a previous estimate of ($1.04).
• B. Riley maintains a "Strong-Buy" rating and a target price of $60 for the stock, while the consensus rating across analysts is currently a "Buy."
• Kymera Therapeutics reported a Q2 earnings miss, posting ($0.95) EPS against a consensus estimate of ($0.83), reflecting a 55.1% year-over-year revenue decline.

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Investment analysts at B. Riley lifted their Q3 2025 earnings per share estimates for shares of Kymera Therapeutics in a research report issued on Tuesday, August 12th. B. Riley analyst M. Mamtani now forecasts that the company will post earnings per share of ($0.98) for the quarter, up from their previous forecast of ($1.04). B. Riley currently has a "Strong-Buy" rating and a $60.00 target price on the stock. The consensus estimate for Kymera Therapeutics' current full-year earnings is ($2.79) per share. B. Riley also issued estimates for Kymera Therapeutics' Q4 2025 earnings at ($1.09) EPS, FY2025 earnings at ($3.82) EPS, FY2026 earnings at ($5.16) EPS, FY2027 earnings at ($5.81) EPS and FY2028 earnings at ($5.29) EPS.

A number of other equities analysts also recently issued reports on KYMR. Jefferies Financial Group set a $64.00 price target on Kymera Therapeutics and gave the company a "buy" rating in a research note on Wednesday, June 25th. Guggenheim reiterated a "buy" rating and set a $60.00 price target on shares of Kymera Therapeutics in a research note on Tuesday, June 3rd. Wall Street Zen upgraded Kymera Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Stifel Nicolaus assumed coverage on Kymera Therapeutics in a research note on Tuesday, May 20th. They set a "buy" rating and a $55.00 price target for the company. Finally, The Goldman Sachs Group raised shares of Kymera Therapeutics to a "strong-buy" rating in a research report on Tuesday, July 15th. Two equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $59.11.

Kymera Therapeutics Stock Performance

KYMR stock opened at $40.73 on Thursday. The company has a market capitalization of $2.91 billion, a P/E ratio of -11.74 and a beta of 2.18. Kymera Therapeutics has a 52-week low of $19.44 and a 52-week high of $53.27. The business has a 50-day simple moving average of $44.86 and a two-hundred day simple moving average of $36.48.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its earnings results on Monday, August 11th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.12). The firm had revenue of $11.48 million during the quarter, compared to analyst estimates of $17.37 million. Kymera Therapeutics had a negative net margin of 616.03% and a negative return on equity of 31.60%. The business's quarterly revenue was down 55.1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.58) earnings per share.

Insider Activity

In other news, Director Jeffrey W. Albers sold 6,349 shares of the business's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $49.00, for a total transaction of $311,101.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Elena Ridloff sold 12,000 shares of the business's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $46.10, for a total transaction of $553,200.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 48,349 shares of company stock worth $2,334,301. Company insiders own 16.01% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Maven Securities LTD purchased a new position in Kymera Therapeutics in the second quarter worth $2,182,000. Diametric Capital LP purchased a new position in Kymera Therapeutics in the second quarter worth $288,000. Marshall Wace LLP grew its position in Kymera Therapeutics by 33.4% in the second quarter. Marshall Wace LLP now owns 269,284 shares of the company's stock worth $11,752,000 after acquiring an additional 67,384 shares in the last quarter. Kennedy Capital Management LLC purchased a new position in Kymera Therapeutics in the second quarter worth $211,000. Finally, Invesco Ltd. grew its position in Kymera Therapeutics by 13.8% in the second quarter. Invesco Ltd. now owns 47,884 shares of the company's stock worth $2,090,000 after acquiring an additional 5,809 shares in the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.